http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2010013918-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2009-06-25^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d869b3a06dec4b8b3fc3fb930bca83fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d545ddbbbf581305ee5517c1e744b90e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_750059893eb23a7930ea56fa1e9527e2 |
| publicationDate | 2011-07-04^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2010013918-A |
| titleOfInvention | MATERIALS AND METHODS TO SUPPRESS AND / OR TREAT NEUROFIBROMA AND RELATED TUMORS. |
| abstract | Germline mutations in the tumor suppressor gene NF1 cause neuron-fibromatosis type 1 (NF1) of Von Recklinghausen, a common genetic disorder of the nervous system characterized by the development of plexiform neurofibromas. Using the adoptive transfer of hematopoietic cells, it is established that the heterozygosity of NF1 from bone marrow derived cells in the tumor microenvironment is sufficient to allow the progress of neurofibromas in the context of the nullification of Schwann cells. In addition, the genetic or pharmacological attenuation of the c-kit signaling pathway in hematopoietic cells greatly decreases the onset and progress of neurofibromas. These studies identify haploinsufficient hematopoietic cells and the c-kit receptor as therapeutic targets to prevent plexiform neurofibromas and involve mast cells as critical mediators of tumor initiation. The administration of therapeutically effective doses of a tyrosine kinase inhibitor such as the imatinib mesylate compound to a patient in need thereof to treat tumors in an affected human patient with a plexiform neurofibroma. |
| priorityDate | 2008-06-27^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 131 of 131.